ADAP
Price
$0.25
Change
-$0.05 (-16.67%)
Updated
May 13, 04:59 PM (EDT)
Capitalization
77.91M
Earnings call today
CSLLY
Price
$75.84
Change
-$0.86 (-1.12%)
Updated
May 12 closing price
Capitalization
73.02B
Ad is loading...

ADAP vs CSLLY

Header iconADAP vs CSLLY Comparison
Open Charts ADAP vs CSLLYBanner chart's image
Adaptimmune Therapeutics
Price$0.25
Change-$0.05 (-16.67%)
Volume$32.3K
Capitalization77.91M
CSL
Price$75.84
Change-$0.86 (-1.12%)
Volume$146.16K
Capitalization73.02B
ADAP vs CSLLY Comparison Chart
Loading...
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CSLLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADAP vs. CSLLY commentary
May 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a Hold and CSLLY is a Hold.

Ad is loading...
COMPARISON
Comparison
May 14, 2025
Stock price -- (ADAP: $0.30 vs. CSLLY: $75.84)
Brand notoriety: ADAP and CSLLY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAP: 47% vs. CSLLY: 145%
Market capitalization -- ADAP: $77.91M vs. CSLLY: $73.02B
ADAP [@Biotechnology] is valued at $77.91M. CSLLY’s [@Biotechnology] market capitalization is $73.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 0 FA rating(s) are green whileCSLLY’s FA Score has 1 green FA rating(s).

  • ADAP’s FA Score: 0 green, 5 red.
  • CSLLY’s FA Score: 1 green, 4 red.
According to our system of comparison, CSLLY is a better buy in the long-term than ADAP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 2 TA indicator(s) are bullish while CSLLY’s TA Score has 4 bullish TA indicator(s).

  • ADAP’s TA Score: 2 bullish, 4 bearish.
  • CSLLY’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ADAP is a better buy in the short-term than CSLLY.

Price Growth

ADAP (@Biotechnology) experienced а -2.48% price change this week, while CSLLY (@Biotechnology) price change was -9.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.49%. For the same industry, the average monthly price growth was +10.87%, and the average quarterly price growth was -7.60%.

Reported Earning Dates

ADAP is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+1.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CSLLY($73B) has a higher market cap than ADAP($77.9M). CSLLY YTD gains are higher at: -12.670 vs. ADAP (-45.201). CSLLY has more cash in the bank: 1.52B vs. ADAP (186M). ADAP has less debt than CSLLY: ADAP (74.5M) vs CSLLY (12B).
ADAPCSLLYADAP / CSLLY
Capitalization77.9M73B0%
EBITDA-55.9MN/A-
Gain YTD-45.201-12.670357%
P/E RatioN/A27.83-
Revenue175MN/A-
Total Cash186M1.52B12%
Total Debt74.5M12B1%
FUNDAMENTALS RATINGS
ADAP vs CSLLY: Fundamental Ratings
ADAP
CSLLY
OUTLOOK RATING
1..100
865
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
2
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9757
PRICE GROWTH RATING
1..100
6576
P/E GROWTH RATING
1..100
10078
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CSLLY's Valuation (2) in the null industry is somewhat better than the same rating for ADAP (58) in the Biotechnology industry. This means that CSLLY’s stock grew somewhat faster than ADAP’s over the last 12 months.

CSLLY's Profit vs Risk Rating (100) in the null industry is in the same range as ADAP (100) in the Biotechnology industry. This means that CSLLY’s stock grew similarly to ADAP’s over the last 12 months.

CSLLY's SMR Rating (57) in the null industry is somewhat better than the same rating for ADAP (97) in the Biotechnology industry. This means that CSLLY’s stock grew somewhat faster than ADAP’s over the last 12 months.

ADAP's Price Growth Rating (65) in the Biotechnology industry is in the same range as CSLLY (76) in the null industry. This means that ADAP’s stock grew similarly to CSLLY’s over the last 12 months.

CSLLY's P/E Growth Rating (78) in the null industry is in the same range as ADAP (100) in the Biotechnology industry. This means that CSLLY’s stock grew similarly to ADAP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAPCSLLY
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
53%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
68%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
70%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
64%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
63%
Advances
ODDS (%)
Bullish Trend 9 days ago
77%
Bullish Trend 9 days ago
51%
Declines
ODDS (%)
Bearish Trend 27 days ago
90%
Bearish Trend 2 days ago
64%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
59%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
52%
View a ticker or compare two or three
Ad is loading...
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CSLLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA318.3820.12
+6.75%
Tesla
AAPL210.7912.52
+6.31%
Apple
SPY582.9918.65
+3.30%
SPDR® S&P 500® ETF
GME28.050.51
+1.85%
GameStop Corp
BTC.X102812.950000-1293.406200
-1.24%
Bitcoin cryptocurrency

ADAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAP has been loosely correlated with AKBA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAP jumps, then AKBA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAP
1D Price
Change %
ADAP100%
+0.89%
AKBA - ADAP
40%
Loosely correlated
-4.71%
ELVN - ADAP
35%
Loosely correlated
+3.20%
AUTL - ADAP
33%
Poorly correlated
+2.27%
CSLLY - ADAP
32%
Poorly correlated
-1.12%
NTLA - ADAP
32%
Poorly correlated
+5.30%
More

CSLLY and

Correlation & Price change

A.I.dvisor tells us that CSLLY and ADAP have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CSLLY and ADAP's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CSLLY
1D Price
Change %
CSLLY100%
-1.12%
ADAP - CSLLY
32%
Poorly correlated
+0.89%
MLYS - CSLLY
32%
Poorly correlated
+2.46%
CDXS - CSLLY
31%
Poorly correlated
+7.32%
SEER - CSLLY
30%
Poorly correlated
+2.72%
ADPT - CSLLY
30%
Poorly correlated
+5.32%
More